Those who had 2 COVID infections were 2.14 times more likely, and those who had 3 or more COVID infections were 3.75 times more likely, to report #LongCOVID than those with one infection.
2/
The odds of both severe fatigue and post-exertional malaise, two debilitating symptoms, increased with reinfections. 3/ #LongCovid
The frequency and severity of post-exertional malaise (PEM) increased with reinfections. 4/ #LongCovid
The severity of fatigue, as measured by the Fatigue Severity Scale, also increased with reinfections. 5/ #LongCovid
The odds of having limitations to physical functioning increased with COVID reinfections, including bathing and dressing limitations, limitations to moderate activity such as pushing a vacuum cleaner, and social limitations. 6/ #LongCovid
Reinfections increased the odds of reporting poor immune health, including having had many other infections and taking longer to recover from common infections. 7/ #LongCovid
The number of vaccines and boosters prior to an infection reduced the odds of Long COVID, but their protective effect was diminished by reinfections. 8/
For those who menstruated, reinfections were associated with worsening of ongoing or chronic health issues related to the menstrual cycle. 9/ #LongCovid
The paper is full of interesting findings, but a few others that stand out:
Only a small percentage reported being prescribed antivirals for acute COVID. 10/
Participants were less likely to report getting a COVID test the more reinfections they experienced, likely due to decreased societal testing over time.
However: they were more likely to test if someone around them tested positive. 11/
Trans, nonbinary, agender, and other gender nonconforming people were less likely to report being prescribed medication for acute COVID. 12/ #LongCovid
The co-authors are all PLRC (@patientled) members who are researchers & have #LongCovid, with affiliations at UCSF, Yale, Howard Hughes Medical Institute, U of Wyoming, U of Bern, U of Bristol, @LongCovidChile & Black COVID-19 Survivors Alliance (@BCSAlliance).
13/
@LongCovidChile @BCSAlliance This was a huge effort over years - thank you @leticiasaurus @TheMegascope & @GinaAssaf for leading & @LisaAMcCorkell @ahandvanish Alison Cohen @jannamoen @LG_Shoemaker Leo Liu @dsethlewis @rach_r0bles @rusty_cjm Jerry Lin, Teri Akintonwa, @ssaraviaandre & @herlifeinpixels! 14/
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We’re happy to announce a new @patientled preprint out today, on machine learning phenotypic with high-dimensional #LongCovid symptom data!
We used a dataset of 162 symptoms in 6,031 participants to explore making clusters of Long Covid patients. 1/ researchsquare.com/article/rs-490…
In sum, we used three different machine learning methods (a genetically optimized deep learning model, ensemble clustering, and probabilistic modeling).
We found that consistent clusters were *not* discovered across the three methods. 2/
This implies both that:
a) symptoms may not be the best way to create phenotypes of #LongCovid patients
b) studies that use fewer symptoms, fewer patients, or only use a single clustering methodology might be detecting phenotypes that are not robust or repeatable
3/
Population-wide, 10.4% of people with pre-existing disabilities had #LongCovid as of summer 2022, vs 7.5% without. 2/
The prevalence of #LongCovid was highest in those with chronic illness (diabetes, asthma) & lowest in those with sensory disabilities (deafness, blindness).
With the exception of sensory disabilities, all disability categories had higher LC rates than the general population. 3/
We’ve released a new paper on designing & optimizing clinical trials for #LongCOVID!
Strong, high-impact trials are critical & most current ones are insufficient. The paper gives guidance on treatments, outcomes, design, participant inclusion, & more.
It also gives an overview of the promising interventions being trialed (as of May 2024) for #LongCovid and their targets, including viral persistence, immune dysfunction, endothelial dysfunction, and symptom management. 2/
Some other key points:
-Trials should prioritize potentially curative interventions, including repurposed drugs and the development of new drugs.
-Combinations of therapies may be beneficial or necessary, which should be considered in clinical trial design. 3/
We are happy to announce a new #LongCovid review out in Nature!
This was led by @zalaly, with co-authors @leticiasaurus @LisaAMcCorkell and @ahandvanish from PLRC, alongside @VirusesImmunity, @EricTopol, and @swulfie.
Today, we are thrilled to see the introduction of The Long COVID Research Moonshot Act by Senator Bernie Sanders (@SenSanders), co-sponsored by Senators @SenTimKaine, @SenDuckworth, @SenMarkey, @SenPeterWelch, and @SenTinaSmith!
9 months ago, our co-founder Lisa McCorkell (@LisaAMcCorkell) & Long COVID researcher Michael Peluso (@MichaelPelusoMD) called for a Moonshot for Long Covid - an investment of at least $1 billion yearly for 10 years into Long Covid research. 2/
The Act is a historic piece of legislation. It includes $1 billion/yr for 10 years to NIH to establish & run a #LongCovid Research Program, led by a Director with expertise in Long COVID. Clinical trials & the development of new interventions would be prioritized & expedited. 3/
"Long COVID is an IACC that occurs after SARS-CoV-2 infection & is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems"
Full report & thoughts👇🧵/1
This #LongCovid definition was developed by @theNASEM — commissioned by @HHSGov through @ASPRgov & OASH — to promote consistency in diagnoses, aid awareness efforts, help patients access care & benefits, harmonize LC research, & public health monitoring/regulations /2
1 pager👇
The definition can be used in clinical care, public health policy, & gives researchers/healthcare workers both consistency & flexibility in studying #LongCovid. Importantly, it also emphasizes how health equity is impacted by & impacts LC. /3